Company / Operating Income
MADRIGAL PHARMACEUTICALS, INC. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$300.1M
FY2025
5-year range
-$497.9M / -$242.5M
FY2021-FY2025
Trend
+39.7%
vs FY2024
Sector context
#163 of 204
Health Care
What the data says
MADRIGAL PHARMACEUTICALS, INC.'s operating income of -$300M is lower than 80% of companies in the Health Care sector (FY2025). Operating Income returned to growth in FY2025 after 8 years of decline, reaching -$300M.
Based on SEC 10-K filings.
-$300M in FY2025.
Improved from -$380M to -$300M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 204This company -$300.1M Sector average $107.7M
▼
-378.6% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 39.7% year-over-year.
- Ranks #163 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2016.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$300.1M | +39.7% |
| FY2024 | -$497.9M | -30.8% |
| FY2023 | -$380.5M | -29.6% |
| FY2022 | -$293.6M | -21.1% |
| FY2021 | -$242.5M | -17.3% |
| FY2020 | -$206.7M | -117.6% |
| FY2019 | -$95.0M | -133.4% |
| FY2018 | -$40.7M | -26.9% |
| FY2017 | -$32.1M | -27.1% |
| FY2016 | -$25.2M | +70.0% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026